CSIMarket
 


Redhill Biopharma Ltd   (RDHL)
Other Ticker:  
 
 

RDHL's Revenue Growth by Quarter and Year

Redhill Biopharma Ltd 's Revenue results by quarter and year




RDHL Revenue (in millions $) FY 2022 FY 2021 FY 2020 FY 2019
IV Quarter December 61.80 85.76 64.36 6.29
III Quarter September 0.00 0.00 0.00 0.00
II Quarter June 0.00 0.00 0.00 0.00
I Quarter March 0.00 0.00 0.00 0.00
FY   61.80 85.76 64.36 6.29



RDHL Revenue fourth quarter 2022 Y/Y Growth Comment
Redhill Biopharma Ltd reported fall in Revenue in the fourth quarter 2022 by -27.94% to $ 61.80 millions, from the same quarter in 2021.
The drop in the fourth quarter 2022 Redhill Biopharma Ltd 's Revenue compares unfavorably to the Company's average Revenue doubling of 139.98%.

Looking into fourth quarter 2022 results within Major Pharmaceutical Preparations industry 202 other companies have achieved higher Revenue growth. While Redhill Biopharma Ltd ' s Revenue drop of -27.94% ranks overall at the positon no. 3639 in the fourth quarter 2022.




RDHL Revenue ( Y/Y Growth %) 2022
2021 2020 2019
IV Quarter December -27.94 % 33.25 % 923.21 % -24.76 %
III Quarter September - - - -
II Quarter June - - - -
I Quarter March - - - -
FY   -27.94 % 33.25 % 923.21 % -41.27 %

Financial Statements
Redhill Biopharma Ltd 's fourth quarter 2022 Revenue $ 61.80 millions RDHL's Income Statement
Redhill Biopharma Ltd 's fourth quarter 2021 Revenue $ 85.76 millions Quarterly RDHL's Income Statement
New: More RDHL's historic Revenue Growth >>


RDHL Revenue (Quarter on Quarter Growth %)

2022
2021 2020 2019
IV Quarter December - - - -
III Quarter September - - - -
II Quarter June - - - -
I Quarter March - - - -
FY (Year on Year)   -27.94 % 33.25 % 923.21 % -41.27 %




Revenue fourth quarter 2022 Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #203
Healthcare Sector #526
Overall #3639

Revenue Y/Y Growth Statistics
High Average Low
923.03 % 139.98 % -100 %
(Dec 31 2020)   0
Revenue fourth quarter 2022 Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #203
Healthcare Sector #526
Overall #3639
Revenue Y/Y Growth Statistics
High Average Low
923.03 % 139.98 % -100 %
(Dec 31 2020)   0

Revenue by Quarter for the Fiscal Years 2019, 2020, 2021, 2022

Redhill Biopharma Ltd 's Q/Q Revenue Growth


Revenue Q/Q Growth Statistics
High Average Low
0 % 0 % 0 %
 


RDHL's IV. Quarter Q/Q Revenue Comment


Revenue Q/Q Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #
Healthcare Sector #
Overall #
Revenue Q/Q Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #
Healthcare Sector #
Overall #
Revenue Q/Q Growth Statistics
High Average Low
0 % 0 % 0 %
 


RDHL's IV. Quarter Q/Q Revenue Comment


Redhill Biopharma Ltd 's 12 Months Revenue Growth Year on Year


Revenue TTM Growth

12 Months Ending
(Dec 31 2022)
12 Months Ending
0
12 Months Ending
(Dec 31 2021)
12 Months Ending
0
12 Months Ending
(Dec 31 2020)
Cumulative Revenue 12 Months Ending $ 61.80 $ 0.00 $ 85.76 $ 0.00 $ 64.36
Y / Y Revenue Growth (TTM) -27.94 % - 33.25 % - 923.03 %
Year on Year Revenue Growth Overall Ranking # 717 # 0 # 0 # 0 # 3776
Seqeuential Revenue Change (TTM) -27.94 % - 33.25 % - 923.03 %
Seq. Revenue Growth (TTM) Overall Ranking # 717 # 0 # 0 # 0 # 3776




Cumulative Revenue growth Comment
Redhill Biopharma Ltd showed decline, but improvement compare to trailing twelve month Revenue decrease in 0. If the fiscal year would end in Dec 31 2022, Redhill Biopharma Ltd 's annual Revenue surge would be -27.94% year on year to $62 millions.

In the Healthcare sector 128 other companies have achieved higher trailing twelve month Revenue growth. While Revenue growth total ranking has deteriorated compare to previous quarter from 0 to 717.

Revenue TTM Q/Q Growth Statistics
High Average Low
923.03 %
241.96 %
-24.75 %
 

Revenue TTM Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry # 59
Healthcare Sector # 129
Overall # 717

Revenue TTM Y/Y Growth Statistics
High Average Low
923.03 %
241.96 %
-24.75 %
 


Revenue TTM Q/Q Growth Company Ranking
Within: No.
Industry # 59
Sector # 129
S&P 500 # 717
Cumulative Revenue growth Comment
Redhill Biopharma Ltd showed decline, but improvement compare to trailing twelve month Revenue decrease in 0. If the fiscal year would end in Dec 31 2022, Redhill Biopharma Ltd 's annual Revenue fall would be -27.94% year on year to $62 millions.

In the Healthcare sector 128 other companies have achieved higher trailing twelve month Revenue growth. While Revenue growth total ranking has deteriorated compare to previous quarter from 0 to 717.

Revenue TTM Q/Q Growth Statistics
High Average Low
923.03 %
241.96 %
-24.75 %
 


Revenue TTM Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry # 59
Healthcare Sector # 129
Overall # 717

Revenue TTM Y/Y Growth Statistics
High Average Low
923.03 %
241.96 %
-24.75 %
 


Revenue TTM Q/Q Growth Company Ranking
Within: No.
Industry # 59
Sector # 129
S&P 500 # 717




Other Revenue Growth
Major Pharmaceutical Preparations Industry Revenue Growth Trends and Statistics
Healthcare Sector Revenue Growth Statistics
Revenue Growth Trends for overall market
RDHL's Revenue Growth Ratio versus Major Pharmaceutical Preparations Industry, Healthcare Sector and total Market
Highest Ranking Revenue Growth
Lowest Ranking Revenue Growth
Revenue Growth for RDHL's Competitors
Revenue Growth for Redhill Biopharma Ltd 's Suppliers
Revenue Growth for RDHL's Customers

You may also want to know
RDHL's Annual Growth Rates RDHL's Profitability Ratios RDHL's Asset Turnover Ratio RDHL's Dividend Growth
RDHL's Roe RDHL's Valuation Ratios RDHL's Financial Strength Ratios RDHL's Dividend Payout Ratio
RDHL's Roa RDHL's Inventory Turnover Ratio RDHL's Growth Rates RDHL's Dividend Comparisons



Companies with similar Revenue fall for the quarter ending Dec 31 2022 within Healthcare SectorY/Y Change %Revenue for the quarter ending Dec 31 2022
Amgen Inc -0.10%$ -0.102 millions
Bausch Health Companies Inc -0.14%$ -0.137 millions
Bio rad Laboratories Inc -0.34%$ -0.339 millions
National Research Corporation-0.40%$ -0.402 millions
Asensus Surgical Inc -0.48%$ -0.485 millions
Teleflex Incorporated-0.51%$ -0.514 millions
Elite Pharmaceuticals Inc -0.62%$ -0.619 millions
Meihua International Medical Technologies Co Ltd -0.66%$ -0.665 millions
Ambrx Biopharma Inc -0.71%$ -0.711 millions
Chemed Corporation-0.85%$ -0.851 millions
Vycor Medical Inc -0.90%$ -0.899 millions
Fonar Corporation-0.91%$ -0.911 millions
Davita Inc -0.92%$ -0.920 millions
Syneos Health Inc -0.98%$ -0.984 millions
Reshape Lifesciences Inc -1.02%$ -1.018 millions
Accuray Incorporated-1.30%$ -1.303 millions
Pliant Therapeutics Inc -1.70%$ -1.701 millions
Royalty Pharma Plc-1.73%$ -1.729 millions
Precipio inc -1.81%$ -1.807 millions
Integra Lifesciences Holdings Corp-1.85%$ -1.850 millions
Novartis Ag-1.98%$ -1.984 millions
Theravance Biopharma inc -1.99%$ -1.987 millions
Uphealth Inc -2.20%$ -2.203 millions
Orthofix Medical Inc -2.27%$ -2.267 millions
Travere Therapeutics Inc -2.41%$ -2.412 millions
Heska Corporation-2.54%$ -2.542 millions
Sangamo Therapeutics Inc -2.70%$ -2.701 millions
Glaukos Corp-2.75%$ -2.748 millions
Community Health Systems Inc -2.85%$ -2.846 millions
Invitae Corporation-2.91%$ -2.908 millions




Help

About us

Advertise

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2024 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com